Short answer
Akebia Therapeutics, Inc. (AKBA) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 earnings released Feb 26, 2026; full results and financials in Exhibit 99.1.
Akebia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 earnings released Feb 26, 2026; full results and financials in Exhibit 99.1
- Key focus: commercial launch performance of Vafseo® (vadadustat), an oral anemia treatment, plus pipeline updates
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Akebia Therapeutics, Inc. 8-K filings
Get the next AKBA 8-K as it lands
Follow AKBA for push alerts, or ask the research agent what this filing means.